Infinity Pharmaceuticals has reported positive results from preclinical and Phase I studies of IPI-549 at the Keystone Symposia Conference.
IPI-549 is an investigational oral immuno-oncology drug designed to treat advanced solid tumours by selectively inhibiting phosphoinositide-3-kinase-gamma (PI3K-gamma).
The data from preclinical study indicated that IPI-549 effects the myeloid cells and remodels the immune-suppressive tumour microenvironment, resulting in elimination of the resistance to immune checkpoint blockade.
The results from the Phase I study conducted in nine patients showed positive safety, pharmacokinetics and pharmacodynamics of IPI-549 as a monotherapy.
The Phase I study involves the evaluation of IPI-549 as a monotherapy and in combination with a PD-1 immune checkpoint inhibitor Opdivo, in patients with advanced solid tumours.
Infinity Pharmaceuticals biology and translational science vice-president Jeffery Kutok said: "The data presented suggest that targeting PI3K-gamma by IPI-549 within immune-suppressive myeloid cells in the tumour microenvironment could offer a unique way to both enhance the activity of checkpoint inhibition in sensitive tumours, as well as to overcome tumour resistance to checkpoint inhibition.
"Infinity is excited to be at the forefront of developing a potentially transformative approach within immuno-oncology, and we look forward to reporting additional data from our Phase I study of IPI-549 later this year."
The firm intends to further base its Phase I study in patients with non-small-cell lung cancer (NSCLC), melanoma, and squamous cell carcinoma of the head and neck (SCCHN), on the data from the preclinical study.